Cell and gene therapy (CGT) has a variety of potential applications in HIV prevention and management. Bibliometric and network analyses suggest potential points of entry for gene therapists into HIV cure research. The existing network of CGT researchers for HIV cure will benefit from an influx of fresh ideas and energy from CGT researchers keen to embrace a new challenge for an old virus.
Get full access to this article
View all access options for this article.
References
1.
DeeksSG, LewinSR, RossAL, et al.International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med, 2016; 22:839–850.
2.
UNAIDS. Seizing the moment: tackling entrenched inequalities to end epidemics. 2020. https://www.unaids.org/sites/default/files/media_asset/2020_global-aids-report_en.pdf (last accessed August19, 2020).
3.
HütterG, NowakD, MossnerM, et al.Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med, 2009; 360:692–698.
4.
GuptaRK, Abdul-JawadS, McCoyLE, et al.HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature, 2019; 568:244–248.
5.
JensenB KE, LübkeN, WensingA, et al.Analytic treatment interruption (ATI) after allogeneic CCR5-D32 HSCT for AML in 2013. CROI Conference on Retroviruses and Opprtunistic Infections, Seattle, Washington, 2019.
6.
ShonoY, DocampoMD, PeledJU, et al.Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med, 2016; 8:339ra71.
7.
ShouvalR, BonifaziF, FeinJ, et al.Validation of the acute leukemia-EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort. Am J Hematol, 2017; 92:429–434.
8.
AlmeidaMJ, MatosA. Designer nucleases: gene-editing therapies using CCR5 as an emerging target in HIV. Current HIV Res, 2019; 17:306–323.
9.
HaworthKG, PetersonCW, KiemHP. CCR5-edited gene therapies for HIV cure: closing the door to viral entry. Cytotherapy, 2017; 19:1325–1338.
10.
TebasP, SteinD, TangWW, et al.Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med, 2014; 370:901–910.
11.
WilliamsRS, LotiaS, HollowayAK, et al.From scientific discovery to cures: bright stars within a galaxy. Cell, 2015; 163:21–23.
12.
BorgattiSP, MehraA, BrassDJ, et al.Network analysis in the social sciences. Science, 2009; 323:892–895.
13.
OmaryMB, EswarakaJ, KimballSD, et al.The COVID-19 pandemic and research shutdown: staying safe and productive. J Clin Invest, 2020; 130:2745–2748.
14.
PaiM. Covidization of research: what are the risks?. Nat Med, 2020; 26:1159.
15.
UNAIDS. Global HIV & AIDS statistics—2020 fact sheet. https://www.unaids.org/en/resources/fact-sheet (last accessed August19, 2020).
16.
McMahonJH, ElliottJH, RoneyJ, et al.Experiences and expectations of participants completing an HIV cure focused clinical trial. AIDS, 2015; 29:248–250.
17.
SimmonsR, KallM, CollinsS, et al.A global survey of HIV-positive people's attitudes towards cure research. HIV Med, 2017; 18:73–79.
18.
DubéK, EvansD, SyllaL, et al.Willingness to participate and take risks in HIV cure research: survey results from 400 people living with HIV in the US. J Virus Erad, 2017; 3:40.e21–50.e21.
19.
FiorentinoM, ProtièreC, Sagaon-TeyssierL, et al.What is the effect of self-identified HIV activism in willingness to participate in HIV cure-related clinical trials? Results from the ANRS-APSEC study. J Virus Erad, 2019; 5:152–162.
20.
DubéK, SimoniJ, LouellaM, et al.Acceptability of cell and gene therapy for curing HIV infection among people living with HIV in the Northwestern United States: a qualitative study. AIDS Res Hum Retroviruses, 2019; 35:649–659.
21.
DelhoveJ, OsenkI, PrichardI, et al.Public acceptability of gene therapy and gene editing for human use: a systematic review. Hum Gene Ther, 2020; 31:20–46.
